secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2023-05-31T23:59:59+00:00
Accession:  0001193125-23-157998
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics announces $50M private placement; extends cash runway into Q1 2025
--------------------------------------------------------------------------------

- Gross proceeds of ~$50M from sale of ~17.7M shares, ~2.4M pre-funded warrants, and ~10.0M purchase warrants at $2.4925 per unit.
- Pre-funded warrants exercisable immediately at $0.001/share, expire May 2028; purchase warrants exercisable from Nov 2023 at $2.673/share, expire Nov 2028.
- Cash, cash equivalents and short-term investments stood at $82.7M as of Q1 2023; combined with net proceeds expected to fund operations into Q1 2025.
- Cantor Fitzgerald and William Blair acted as joint lead placement agents; H.C. Wainwright as co-placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000119312523157998/0001193125-23-157998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000119312523157998/d515559d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-157998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer